Quantitative benefit-risk analysis for evaluating drug therapies.

Area of Science:

• Pharmacology and Drug Development
• Biostatistics
• Regulatory Science

Background:

• Benefit-risk analysis is crucial for drug approval and post-market surveillance.
• Existing quantitative tools for formal benefit-risk assessment are limited.
• Balancing drug efficacy against adverse events is a key challenge in pharmaceutical review.

Purpose of the Study:

• To propose a novel quantitative method for benefit-risk analysis of pharmaceutical drugs.
• To identify an optimal drug dosage that maximizes the difference between therapeutic benefit and risk of adverse side effects.
• To incorporate costs associated with lack of benefit and adverse events into the analysis.

Main Methods:

• Utilized receiver operating characteristic (ROC) curves as the core quantitative tool.
• Developed a method to find an optimal dose by maximizing the differential between benefit and risk.
• Enabled separate analysis for subpopulations and different adverse events.

Main Results:

• The proposed ROC curve method provides a quantitative framework for benefit-risk assessment.
• The method allows for the identification of optimal drug doses tailored to specific contexts.
• The approach facilitates a comprehensive understanding of trade-offs between drug benefits and risks.

Conclusions:

• The quantitative ROC curve method offers a valuable tool for optimizing drug dosage and improving drug safety.
• This approach can support selective drug approval for specific subpopulations or at varied doses.
• The method enhances the precision of benefit-risk evaluations in pharmaceutical decision-making.